PCH
Polar Capital Holdings Portfolio holdings
AUM
$19.1B
1-Year Return
55.52%
This Quarter Return
+17.9%
1 Year Return
+55.52%
3 Year Return
+234.94%
5 Year Return
–
10 Year Return
–
AUM
$15.4B
AUM Growth
–
Cap. Flow
+$15.4B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
26.84%
Holding
317
New
317
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Apple
AAPL
|
$768M |
| 2 |
Microsoft
MSFT
|
$710M |
| 3 |
Meta Platforms (Facebook)
META
|
$546M |
| 4 |
Amazon
AMZN
|
$373M |
| 5 |
Advanced Micro Devices
AMD
|
$354M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 38.38% |
| 2 | Healthcare | 19.7% |
| 3 | Financials | 14.71% |
| 4 | Communication Services | 12.81% |
| 5 | Consumer Discretionary | 8.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Fiserv
FI
$73.4B
| $27.7M | 0.17% |
+243,343
| New | +$27.7M |
|
127
Summit Therapeutics
SMMT
$19.3B
| $27.3M | 0.17% |
+5,800,000
| New | +$27.3M |
|
128
US Foods
USFD
$17.5B
| $27.1M | 0.16% |
+814,626
| New | +$27.1M |
|
129
Alnylam Pharmaceuticals
ALNY
$59.2B
| $26.3M | 0.16% |
+202,000
| New | +$26.3M |
|
130
Y-mAbs Therapeutics
YMAB
$390M
| $25.1M | 0.15% |
+507,633
| New | +$25.1M |
|
131
Littelfuse
LFUS
$6.51B
| $24.7M | 0.15% |
+97,014
| New | +$24.7M |
|
132
Accenture
ACN
$159B
| $24.5M | 0.15% |
+93,852
| New | +$24.5M |
|
133
Ametek
AME
$43.3B
| $24.3M | 0.15% |
+200,610
| New | +$24.3M |
|
|
CFXA
134
DELISTED
Colfax Corporation 5.75% Tangible Equity Units
CFXA
| $24.2M | 0.15% |
+150,000
| New | +$24.2M |
|
135
Insmed
INSM
$30.7B
| $23.3M | 0.14% |
+701,301
| New | +$23.3M |
|
136
Surgery Partners
SGRY
$2.89B
| $23.2M | 0.14% |
+799,054
| New | +$23.2M |
|
137
AtriCure
ATRC
$1.76B
| $22.9M | 0.14% |
+411,976
| New | +$22.9M |
|
138
BlackLine
BL
$3.32B
| $22.9M | 0.14% |
+171,372
| New | +$22.9M |
|
139
DexCom
DXCM
$31.6B
| $22.7M | 0.14% |
+245,812
| New | +$22.7M |
|
|
TRIL
140
DELISTED
Trillium Therapeutics Inc.
TRIL
| $22.5M | 0.14% |
+1,532,922
| New | +$22.5M |
|
141
Globus Medical
GMED
$8.18B
| $22.4M | 0.14% |
+342,858
| New | +$22.4M |
|
142
AptarGroup
ATR
$9.13B
| $22.3M | 0.14% |
+163,012
| New | +$22.3M |
|
143
ADC Therapeutics
ADCT
$398M
| $21.9M | 0.13% |
+683,837
| New | +$21.9M |
|
144
Taylor Morrison
TMHC
$7.1B
| $21.8M | 0.13% |
+850,393
| New | +$21.8M |
|
145
Arcutis Biotherapeutics
ARQT
$2.06B
| $21.8M | 0.13% |
+775,000
| New | +$21.8M |
|
|
GBT
146
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $21.7M | 0.13% |
+500,000
| New | +$21.7M |
|
147
Kulicke & Soffa
KLIC
$1.99B
| $21.5M | 0.13% |
+674,849
| New | +$21.5M |
|
148
ProAssurance
PRA
$1.22B
| $21.3M | 0.13% |
+1,200,000
| New | +$21.3M |
|
|
SGEN
149
DELISTED
Seagen Inc. Common Stock
SGEN
| $21M | 0.13% |
+120,000
| New | +$21M |
|
150
Bristol-Myers Squibb
BMY
$96B
| $20.6M | 0.13% |
+332,843
| New | +$20.6M |
|